References
- Tabor E, Gerety R J, Vogel CL, et al. Hepatitis B virus infection and primary hepatocellular carcinoma. J Natl Cancer Inst 1977; 58: 1197–1200
- Bréchot C, Hadchouel M, Scotto J, et al. State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigenpositive and -negative liver diseases. Proc Natl Acad Sci (USA) 1981; 78: 3906–3910
- Summers J, O'Connell A, Maupas P, et al. Hepatitis B virus DNA in primary hepatocellular carcinoma tissue. J Med Virol 1978; 2: 207–214
- Koshy R, Maupas P, Müller R, Hofschneider PH. Detection of hepatitis B virus-specific DNA in the genomes of human hepatocellular carcincoma and liver cirrhosis tissues. J Gen Virol 1981; 57: 95–102
- Wands J R, Mann E, Alpert E, Isselbacher KJ. The pathogenesis of arthritis associated with acute hepatitis-B surface antigen-positive hepatitis: Complement activation and characterization of circulating immune complexes. J Clin Invest 1975; 55: 930–936
- Gocke D J, Hsu K, Morgan C, et al. Vasculitis in association with Australia antigen. J Exp Med 1971; 134: 330s–336s
- Takekoshi Y, Tanaka M, Miyakawa Y, et al. Free ‘small’ and IgG-associated ‘large’ hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med 1979; 300: 814–819
- Brzosko W J, Krawczynski K, Nazarewicz T, et al. Glomerulonephritis associated with hepatitis-B surface antigen immune complexes in children. Lancet 1974; 2: 477–482
- Slusarczyk J, Michalak T, Nazarewicz-de Mezer T, et al. Membranous glomerulopathy associated with hepatitis B core antigen immune complexes in children. Am J Pathol 1980; 98: 29–44
- Lisker-Melman M, Webb D, Di Bisceglie AM, et al. Glomerulonephritis caused by chronic hepatitis B virus infection: Treatment with recombinant human alpha-interferon. Ann Int Med 1989; 111: 479–483
- Coursaget P, Barres J L, Tortey E, et al. Persistence of circulating complexes between HBsAg and immunoglobulin M in sera of hepatitis B surface antigen positive patients suffering from liver cirrhosis or primary liver cancer. Cancer Res 1986; 46: 1492–1494
- Brown S E, Steward M W, Viola L, et al. Chronic liver disease: the detection and characterization of circulating immune complexes. Immunology 1983; 49: 673–683
- Brown S E, Howard C R, Steward MW, et al. Hepatitis B surface antigen containing immune complexes occur in seronegative hepatocellular carcinoma patients. Clin Exp Immunol 1984; 55: 355–359
- Celada A, Barnet M, Aguado MT, et al. Ferritin levels and circulating immune complexes in patients with solid tumors. Bull Cancer (Paris) 1982; 69: 22–27
- Arima T, Narumoto J, Shimomura H, et al. Studies on circulating immune complexes of the liver disease. 4. Clq binding activity. Gastroenterologia Japonica 1980; 15: 27–31
- Munoz L E, De Villiers D, Markham D, et al. Complement activation in chronic liver disease. Clin Exp Immunol 1982; 47: 548–554
- Neri B. Circulating immune complexes as ‘tumor marker’ in hepatoma-bearing rats (Yoshida AH 130). Immunol Lett 1983; 6: 59–61